Last updated: 2026-10-12 06:42:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Anixa Biosciences, Inc. (ANIX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.89, with a market capitalization of $100.82M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.32 to $5.46. This page covers its latest market performance, valuation, price trends and company information.
$100.82M | |
$2.93 | |
$8.09 | |
$1.33 | |
$2.91 | |
208.25K | |
305.77K | |
-- | |
$5.46 | |
$2.32 | |
-- | |
-- |
Anixa Biosciences, Inc. (ANIX) last closed at $2.91 as of 2026-10-09 23:58:00, unchanged from the previous close of $2.91.
During the latest regular trading session, ANIX traded between $1.33 and $8.09, with a volume of 208.25K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Anixa Biosciences, Inc. (ANIX) moved from $2.77 to $2.89, representing a gain of 4.44% ($0.12).
The stock traded between $2.74 and $3.11 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 308.91 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 18.3%
ANIX is currently trading at $2.89, placing it 18.3% of the way from its 52-week low of $2.32 to its 52-week high of $5.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 4 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Anixa Biosciences, Inc. (ANIX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.